|
Maya's Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: Simcere outlines global R&D expansion, Sanyou Bio and NovoCodex develop dual-payload ADCs, and FDA leaders address AI, UV filters, and supply-chain security.
The top 10 stories from Thu Sep 24, 2026 06:57 AM to Fri Sep 25, 2026 06:57 AM
Generated September 25, 2026 at 6:57 AM
|
|
|
#1 CHPA RSQ Conference: From AI To UV Filters, NAMs To Supply Chain Security Published 2026-09-25 FDA leaders will present at the Consumer Healthcare Products Association’s September 28–30 conference on AI, UV filters, new approach methodologies, and supply-chain security. Covered by: insights.citeline.com |
#2 Strategic Collaboration | Sanyou Bio and NovoCodex Partner to Co-Develop Innovative Dual-Payload ADCs Published 2026-09-24 Sanyou Bio and NovoCodex entered a strategic collaboration to co-develop dual-payload antibody-drug conjugates (ADCs). Covered by: prnewswire.com |
#3 Earendil Labs Announces Research Collaboration with Genentech to Discover and Develop Therapeutic Bispecific Antibodies in Oncology Published 2026-09-24 Earendil Labs announced a research collaboration with Genentech to discover and develop multiple therapeutic bispecific antibodies for oncology. Covered by: prnewswire.com, endpoints.news |
#4 How radioligand therapy is rewriting cancer care Published 2026-09-24 Curium executives discuss radioligand therapy’s diagnostic and therapeutic applications and its potential impact on cancer care for more than 14 million patients worldwide. Covered by: biospace.com |
#5 Network Bio: Building disease-specific AI models with biobank data Published 2026-09-25 Palo Alto-based Network Bio uses patient-derived tissue biobank data to develop disease-specific AI models aimed at tracking disease progression and enabling earlier detection and treatment. Covered by: biocentury.com |
#6 Elevar wins first FDA approval with second-line drug for bile duct cancer Published 2026-09-24 The FDA approved Elevar Therapeutics’ Lyrfigtu as a second-line treatment for certain bile duct cancer patients, marking the company’s first approval. Covered by: endpoints.news |
#7 Simcere Envisions World-Facing R&D To Scale Up Global Partnerships Published 2026-09-24 Simcere plans to expand its global partnerships through a world-facing research and development strategy supporting future licensing deals. Covered by: insights.citeline.com |
#8 Precision Radiation Therapy Alone Doubles Historical Survival Rates for Inoperable Lung Cancer, Landmark Lancet Trial Finds Published 2026-09-24 A Phase III Lancet trial reported 82% two-year survival for patients with inoperable lung cancer treated with precision radiation therapy alone. Covered by: prnewswire.com |
#9 FDA Panel Backs GRAIL’s Multi-Cancer Test, But Split Votes Put ‘Early Detection’ Claim In Play Published 2026-09-24 An FDA panel backed GRAIL’s multi-cancer test, but divided votes questioned whether its “early detection” claim demonstrates improved disease outcomes. Covered by: insights.citeline.com |
#10 Marathon Fusion Publishes New Pathway for Scalable Production of Promising Cancer-Treatment Isotope Terbium-149 Published 2026-09-24 Marathon Fusion researchers propose a stable gadolinium precursor that could enable Tb-149 production on widely available medical cyclotrons, addressing a longstanding isotope-supply bottleneck. Covered by: prnewswire.com |
